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CONCLUSION:
Clinical and Genetic Spectra of Autosomal Dominant Tubulointerstitial 
Kidney Disease due to Mutations in UMOD and MUC1
Largest international retrospective ADTKD cohort study:  
 Detailed clinical and genetic phenotyping of         
ADTKD-UMOD & ADTKD-MUC1
 Uromodulin biology is not altered in ADTKD-MUC1
 Clinical and biochemical UMOD-score discriminates 
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Autosomal dominant tubulointerstitial kidney diseas (ADTKD) is an increasingly recognized 
cause of end-stage kidney disease, primarily due to mutations in UMOD and MUC1. The lack of 
clinical recognition and the small size of cohorts have slowed the understanding of disease 
ontology and development of diagnostic algorithms. To expand on this, we analyzed two 
registries from Europe and the United States to define genetic and clinical characteristics of 
ADTKD-UMOD and ADTKD-MUC1 and develop a practical score to guide genetic testing. Our 
study encompassed 726 patients from 585 families with a presumptive diagnosis of ADTKD 
along with clinical, biochemical, genetic and radiologic data. Collectively, 106 different UMOD 
mutations were detected in 216/562 (38.4%) of families with ADTKD (303 patients), and 4 
different MUC1 mutations in 72/205 (35.1%) of the families that are UMOD-negative (83 
patients). The median kidney survival was significantly shorter in patients with ADTKD-MUC1 
compared to ADTKD-UMOD (46 vs. 54 years respectively), whereas the median gout-free 
survival was dramatically reduced in patients with ADTKD-UMOD compared to ADTKD-
MUC1 (30 vs. 67 years respectively). In contrast to patients with ADTKD-UMOD, patients with 
ADTKD-MUC1 had normal urinary excretion of uromodulin and distribution of uromodulin in 
tubular cells. A diagnostic algorithm based on a simple score coupled with urinary uromodulin 
measurements separated patients with ADTKD-UMOD from those with ADTKD-MUC1 with a 
sensitivity of 94.1%, a specificity of 74.3% and a positive predictive value of 84.2% for a 
UMOD mutation. Thus, ADTKD-UMOD is more frequently diagnosed than ADTKD-MUC1, 
ADTKD subtypes present with distinct clinical features, and a simple score coupled with urine 
uromodulin measurements may help prioritizing genetic t sting. 
 




Autosomal dominant tubulointerstitial kidney diseas (ADTKD) is characterized by tubular 
damage and interstitial fibrosis of the kidney in the absence of glomerular lesions. Affected 
individuals present with progressive chronic kidney disease (CKD), normal-to-mild proteinuria 
and normal sized kidneys, often with a positive family history 1,2. The disease invariably 
progresses to end-stage kidney disease (ESKD). Dominant mutations in UMOD were first 
associated with ADTKD 3,4. UMOD encodes uromodulin, a kidney-specific protein thatis 
abundant in normal urine and plays multiple roles in the kidney 4. Mutations in MUC1 were 
subsequently identified as a cause for ADTKD 5. MUC1 encodes the glycoprotein mucin-1, 
which is important in epithelial barrier function ad intracellular signaling 6-8. Rare forms of 
ADTKD have also been associated with mutations in HNF1B, which encodes for the 
transcription factor hepatocyte nuclear factor 1β (HNF1β) 9,10; REN, which encodes preprorenin, 
the precursor of renin 11; and SEC61A1, which encodes the α1 subunit of the SEC61 complex 
that forms the core of the endoplasmic reticulum (ER) translocon 12.  
Due to the non-specific nature of the clinical, biological and pathological findings, 
ADTKD is underdiagnosed. In a recent study of whole exome sequencing in ~3000 CKD 
patients, UMOD mutations were detected in 3% of patients with a monogenic cause of CKD, 
making it the 6th most common genetic diagnosis in CKD 13. A single tertiary center survey in 
England estimated that up to 2% of patients with ESKD had ADTKD-UMOD, i.e. the most 
common monogenic kidney disease after autosomal dominant polycystic kidney disease 
(ADPKD) 14. The prevalence of ADTKD-MUC1 remains unclear, as mutations in MUC1 are not 
detected by next generation sequencing and require specialized genetic testing 5,13. However, 
previous studies have identified ADTKD-MUC1 and ADTKD-UMOD as the most common 
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subtypes of ADTKD 15,16. The pathophysiology of ADTKD-UMOD involves retention of mutant 
uromodulin in the endoplasmic reticulum (ER) with ensuing ER stress (“gain of toxic function”) 
and a cascade leading to inflammatory cell infiltrate, tubular dysfunction and interstitial fibrosis 
17-19. ADTKD-MUC1 is caused by mutations in the variable number of tandem repeat (VNTR) 
region of mucin-1, leading to the formation of a frmeshift, truncated protein (MUC1fs) that 
accumulates in intracellular vesicles and cause tubulointerstitial damage 20.  
To date, the largest clinical analysis of ADTKD-UMOD was performed in a cohort of 
French and Belgian ADTKD-UMOD patients (n=70 from 38 families), showing a median renal 
survival of 54 years and a 66% prevalence of gout 21. The phenotype of ADTKD-MUC1 patients 
was reported in a cohort of 95 patients from 24 families, with an age of onset of ESKD ranging 
from 16 to 80 years and a 24% prevalence of gout 8. A Spanish cohort of 90 ADTKD-MUC1 
patients (16 families) showed a trend towards earlir age at ESKD and a lower prevalence of 
gout compared to ADTKD-UMOD patients (n=41 from 9 families). The small size of these 
cohorts prevented the detection of significant differences between ADTKD subtypes 16. 
Because of the nonspecific presentation and relativ rarity, a clinical characterization of 
ADTKD subtypes and practical tools to guide genetic testing for suspected ADTKD are missing. 
Here, we compared the phenotype of the ADTKD-UMOD and ADTKD-MUC1 subgroups in two 
large cohorts from Europe (Belgo-Swiss ADTKD Registry) and the US (US ADTKD Registry) - 
representing the largest multicenter ADTKD cohort (726 patients from 585 families) to date. We 
observed distinct features among these ADTKD subtypes and established a simple score to orient 




Clinical and genetic characteristics of ADTKD patients 
The International ADTKD Cohort included 726 patients from 585 families: 451 patients from 
429 families from the US ADTKD Registry and 275 patien s from 156 families from the Belgo-
Swiss ADTKD Registry (Figure 1). 84% of patients presented with CKD, and 43% had reached 
ESKD. Gout had an overall prevalence of 66% and a family history of either CKD and/or gout 
was reported in 92% of all cases (Table 1). The main differences between the Belgo-Swiss and 
US Registries included age at presentation, which was older, and prevalence of ESKD, which 
was higher in the US Registry, possibly due to a higher rate of patient self-referral when the 
disease became symptomatic.  
Most patients (703/726), from 562/585 families, underwent mutational screening in the UMOD 
gene as a first diagnostic test. UMOD mutations were detected in 216 out of 562 tested families 
(38.4%), corresponding to 303 out of 703 tested patients (43.1%) (Figure 1). The UMOD 
mutation detection rate was 40.0% in the US Registry and 34.6% in the Belgo-Swiss Registry 
(Table 1). Next, mutations in MUC1 were screened in 218 UMOD-negative patients, from 205 
UMOD-negative families, mostly from the US Registry. Of these, 83 patients from 72 families 
screened positive for MUC1 mutations, yielding a proportion of 35.1% (72/205) families with 
ADTKD-MUC1 among UMOD-negative ADTKD families. Of note, a subset of 23 patients from 
23 ADTKD families (most of them previously linked to chromosome 1q22) were first screened 
for MUC1, with a mutation in MUC1 detected in 21 of patients in this group (Figure 1). At the 
end of the screening process, 135 patients from 133 families were negative for mutations in both 
UMOD and MUC1 (Figure 1). Based on these genetic results, the prevalence for ADTKD-
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UMOD is 37.1% [216 positive /(585-2) tested families] and for ADTKD-MUC1 is 21.0% [93 
positive /(585-141) tested families] among ADTKD families in this real-life cohort.  
 
Spectrum of UMOD and MUC1 mutations 
A total of 106 different UMOD mutations were detected in the 216 ADTKD-UMOD families 
(Figure 2A; Table S1). Variant calling was based on in silico prediction tools, previous reports 
and/or family segregation analysis for undescribed variants. Missense mutations were by far the 
most common type of UMOD mutations (101/106, 95.3%). Four different deletions (H177-
R185del, E188-L221del, K246-S252del, Y272del) and oe insertion-deletion (V93-G97del4ins) 
mutations were found. 95/106 (89.6%) mutations were clustered in exon 3 of the UMOD gene. 
57/101 (56.4%) of all missense mutations involved cysteine bonds, either by substituting a 
cysteine residue by another amino acid or by inserting a new cysteine (Figure 2B). Among the 17 
mutations not described before (Table S1), 6 involve a previously reported amino acid (N85S, 
C92G, C120R, C135W, V273L, C300S); two (Y272del, G201D) were validated in segregation 
analyses; and one (L284P) was clearly associated with ER retention in functional studies, similar 
to paradigm mutation C150S (Figure S1), along with family history (Three generations with 
CKD and gout, bland urine sediment) and the absence of this substitution in gnomAD. The 
remaining eight mutations were predicted disease causing using in silico prediction tools (Table 
S2).  
We detected two families with genetically proven de novo UMOD mutations c.855C>A 
(p.A285E) and c.707C>T (p.P236L) and one family with clinically suspected neo-mutation 
c.707C>T (p.P236L). We did not detect UMOD mutations in the homozygous state.  
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Four different types of MUC1 mutations (27dupC; 28dupA; 26_27insG; 23delinsAT) in the 
VNTR domain of MUC1 were detected in this cohort (nomenclature based on the mutation 
position inside the canonical 60 nucleotide long wild-type VNTR repeat as identified by MUC1 
VNTR sequencing 7). Their localization inside the MUC1 VNTR as well as their effect on the 
mucin-1 protein structure are shown in Figure 2C. All these mutations are predicted to lead to the 
same frame-shift and premature stop codon 7. Among the 93 ADTKD-MUC1 families, 87 
presented with a cytosine duplication (27dupC, 93.5%), three with an adenine duplication 
(28dupA, 3.2%) and two with a guanine insertion (26_ 7insG, 2.2%) and one with a small indel 
(23delinsAT, 1.1%)(Figure 2D).  
 
Clinical characteristics of ADTKD-UMOD and ADTKD-MUC1  
The size of the International ADTKD Cohort allowed us to analyze the clinical characteristics of 
ADTKD-UMOD and ADTKD-MUC1 subtypes (Figure 3). Age at presentation (first patient 
contact) was earlier (median: 42 years [IQR 27; 53] vs. 47 years [IQR 37; 57], p=0.005) and a 
positive family history of CKD and/or gout more frequent (95% vs. 86%, p=0.007) in ADTKD-
UMOD compared to ADTKD-MUC1 patients. While the overall prevalence of CKD was 
significantly higher in ADTKD-UMOD patients, ESKD was significantly more prevalent (44% 
vs. 58%, p=0.04) and of earlier onset (median: 46 years [IQR 39; 57] vs. 36 years [IQR 30; 46], 
p<0.001) in ADTKD-MUC1 patients (Figure 3B upper panel). Conversely, the prevalence of 
gout was significantly higher (79% vs. 26%, p<0.001) and gout onset was significantly earlier 
(median: 27 years [IQR 19; 37]vs. 45 years [IQR 29; 51], p=0.001) in ADTKD-UMOD patients 
(Figure 3B lower panel). These findings were generally consistent in both genders. In ADTKD-
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UMOD patients, gout onset was significantly earlier in men compared to women (median: 26 
years [IQR 18; 34] vs. 30 years [IQR 21; 43], p=0.013) (Figure 3A).  
The key differences in terms of renal function and uric acid handling were substantiated by 
survival curves depicting freedom from ESKD and gout (Figure 4). Renal survival was 
significantly shorter in ADTKD-MUC1 compared to ADTKD-UMOD (Median: 54 years, 95% 
CI: 51.5-56.5) in ADTKD-UMOD vs. 46 years, 95% CI: 39.3-52.7 in ADTKD-MUC1, log rank 
test: p=0.013) (Figure 4A). Conversely, gout free survival was dramatically shorter in ADTKD-
UMOD compared to ADTKD-MUC1 (Median: 30 years, 95% CI: 27.3-32.7 in ADTKD-UMOD 
vs. 67 years, 95% CI: 57.9-76.1 in ADTKD-MUC1, log rank test: p<0.001) (Figure 4B).  
Among ADTKD-UMOD patients, carriers of missense mutations involving cysteines (either by 
substituting a cysteine residue by another amino acid or by inserting a new cysteine) did not 
experience a worse prognosis in terms of onset of ESKD or age of gout onset when compared 
with non-cysteine-involving ADTKD-UMOD patients (Figure S2).  
Comparing ADTKD-UMOD with ADTKD-NOS (not otherwise specified, i.e. no mutation 
detected) in the US ADTKD Registry, we found that CKD (94.0% vs. 82.7%, p<0.001) and 
ESKD (46.5% vs. 26.2%, p<0.001) were more prevalent and the eGFR at diagnosis lower 
(34.7ml/min vs. 48.1ml/min, p<0.001) in ADTKD-UMOD vs. ADTKD-NOS, respectively. 
Similarly, CKD and ESKD were more prevalent in ADTKD-MUC1 compared to ADTKD-NOS 
(86.4% vs. 82.7%, p<0.001 and 54.8% vs. 26.2%, p<0.001, respectively) (Table S3). These 
findings suggest a more severe kidney phenotype in ADTKD-UMOD and ADTKD-MUC1 
compared to ADTKD cases without genetic diagnosis – a finding confirmed in the Belgo-Swiss 




Uromodulin biology in ADTKD-UMOD and ADTKD-MUC1 
Given the colocalization of mucin-1 with uromodulin in the kidney tubule 6 and the fact that 
MUC1fs accumulates in several tissues without causing extrarenal manifestations 7, we tested the 
hypothesis that MUC1fs might interact with uromodulin processing in the TAL in ADTKD-
MUC1. We used a validated ELISA 22 to assess the levels of urinary uromodulin in a population-
based cohort (Cohorte Lausannoise), confirming the positive correlation between urinary 
uromodulin (mg/g creatinine) and eGFR between 15 and 90mL/min/1.73m2 (Figure S3A, test for 
linear trend, p: 0.001), as previously described 23. Normalizing urinary uromodulin for eGFR (in 
addition to urinary creatinine) mitigated the linear dependency (Figure S3B, test for linear trend, 
p: 0.54), allowing a more robust comparison of urinary uromodulin levels between patients and 
controls. We next measured urinary uromodulin levels in ADTKD-MUC1 and ADTKD-UMOD 
patients, compared to controls (n=180) from the population-based cohort strictly matched for 
eGFR (45-60mL/min/1.73m2). In contrast to ADTKD-UMOD patients, who showed strongly 
reduced urinary uromodulin levels (Median: 2.8 vs. 14.7mg/g creatinine, p<0.0001), ADTKD-
MUC1 patients showed urinary levels of uromodulin similar to controls (Median: 15.7 vs. 
14.7mg/g creatinine, p=0.99) (Figure 5A left panel). Normalizing urinary uromodulin levels to 
eGFR (mg/g creatinine/eGFR) confirmed strongly reduc  levels in ADTKD-UMOD vs. 2717 
controls with eGFR spanning 15-90 mL/min/1.73m2 (0.05 vs. 0.23mg/g creatinine/eGFR, 
p<0.0001, respectively), in contrast with unchanged levels in ADTKD-MUC1 vs.  controls (0.29 
vs. 0.23mg/g creatinine/eGFR, p=0.29, respectively) (Figure 5A right panel). 
Next, we performed immunofluorescence staining for ur modulin on kidney biopsies from 
healthy individuals (NHK, normal human kidney), from two ADTKD-UMOD patients and from 
two ADTKD-MUC1 patients. While we were able to see the characteristic intracellular 
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uromodulin deposits in the ADTKD-UMOD patients, uromodulin staining was largely confined 
to the apical membrane in ADTKD-MUC1 patients, similar to the pattern observed in normal 
kidney (Figure 5B). The accumulation of mutant uromodulin in the TAL cells from ADTKD-
UMOD patients induced ER stress, as shown by colocalization with the unfolded protein 
response (UPR) regulator GRP78 (also known as Binding immunoglobulin protein, BiP). 
Conversely, GRP78 could not be detected in the TALs of ADTKD-MUC1 patients (Figure 5B; 
Figure S4).  
 
Establishment of a clinical UMOD-score in the Belgo-Swiss ADTKD Registry 
Based on the Belgo-Swiss ADTKD Registry with detaild phenotyping, including 54 UMOD-
positive families (n=132 patients) and 102 UMOD-negative families (n=143 patients) (Figure 1; 
Figure S5), we designed a clinical score to estimate the probability of ADTKD-UMOD. Clinical 
characteristics in ADTKD patients with/without UMOD mutations guided the scoring system 
(Figure S6). Compared to UMOD-negative patients, patients with a UMOD mutation had a more 
frequent family history of CKD and/or gout (90% vs.76%, p<0.001); a higher prevalence of 
CKD (83% vs. 75%, p=0.03) and ESKD (33% vs. 20%, p=0.02), with earlier onset of CKD 
(Median: 32 years vs. 42 years, p=0.002) and ESKD (Median: 42 years vs. 48 years, p=0.007); a 
higher level of serum uric acid (Mean: 507.0±131 vs. 454.5±153.4µmol/L, p=0.017) and an 
earlier onset of gout (Median: 24 years vs. 33 years, p=0.001). Of note, the prevalence of renal 
cysts, as detected by sonography and/or computed tomography or magnetic resonance imaging, 
was lower in ADTKD-UMOD compared to UMOD-negative patients (36% vs 57%, p=0.001) 
(Figure S6).  
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The weighted UMOD-score was developed on eight items using these discrim native clinical, 
biochemical, histological and imaging characteristics of ADTKD-UMOD (Figure 6A). The 
maximal item value of +3 points was attributed to gout before 30 years and uricemia 
>500µmol/L - the most specific discriminants (Figure S6). Since the prevalence of CKD and 
autosomal dominant inheritance was higher in ADTKD-UMOD, these criteria were weighted 
with +2 points. Clinical findings suggesting an alternative diagnosis (eg. proteinuria, 
uncontrolled hypertension) were attributed negative points. Values for each available item are 
added in order to obtain a final additive score for each patient. The clinical UMOD score was 
applied on ADTKD patients from the Belgo-Swiss Registry, for which information for at least 
5/8 items were present (n=211: 106 UMOD-positive and 105 UMOD-negative patients). The 
receiver operating characteristics (ROC) curve, with UMOD mutation status as the dependent 
variable yielded an area under the curve (AUC) of 0.72 (95% CI 0.66; 0.79, P<0.001) (Figure 
6B). The UMOD score cut-off of ≥5 was selected, yielding a sensitivity of 98.1% andspecificity 
of 41.4% for positive UMOD mutation testing, corresponding to a negative predictive value 
(NPV) of 94.3% and a positive predictive value (PPV) of 59.1% (Figure 6C; Table S4). This cut-
off also proved to be optimal for group discriminaton corresponding to a Youden index 
(sensitivity+specificity-1) of 0.395 (Table S4). 
 
The UMOD-score and urine uromodulin levels to guide genetic testing in ADTKD  
The score was validated in UMOD-positive (n=124) and UMOD-negative (n=183) patients from 
the US ADTKD Registry, yielding similarly high sensitivity and low specificity for UMOD 
mutations using a cut-off of ≥5 (Sensitivity: 97.6%, specificity: 16.4%, NPV: 91.0%, PPV: 
44.2%, data not shown), altogether making ADTKD-UMOD very unlikely for score results <5. 
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We tested how the clinical score separated the two most common etiologies of ADTKD in a 
subset of ADTKD-UMOD (n=125) and ADTKD-MUC1 (n=80) patients from the US Registry 
for which at least 5/8 clinical item and/or urinary uromodulin levels were available. The clinical 
UMOD-score alone separated the two entities with an AUC of 0.69 (95% CI 0.62; 0.77, p=0.037) 
(Figure 7A left panel). However, the specificity for UMOD increased considerably with higher 
UMOD-score values (for instance score ≥8 had a sensitivity of 48.8%, a specificity of 83.7%, a 
NPV of 50.8% and a PPV of 81.3% for an UMOD mutation) (Table S5). Only a few, mostly 
ADTKD-MUC1 patients had score results of <5 (Figure 7A right panel).  
We next investigated whether addition of urinary uromodulin levels to the clinical score 
improved its ability to discriminate ADTKD-UMOD from ADTKD-MUC1. Based on the 
normalized urinary uromodulin values in the reference population (mg/g creatinine/eGFR) 
(Figure 5A right panel), we assigned respectively +1 and +3 points for urinary uromodulin 
values between the median and 25th percentile (0.14-0.23 mg/g creatinine/eGFR) and below the 
25th percentile. Similarly, we assigned respectively -1 and -3 points for urinary uromodulin 
values between the median and 75th percentile (0.23-0.35 mg/g creatinine/eGFR) and above the 
75th percentile. Applied to a cohort of 51 ADTKD-UMOD and 35 ADTKD-MUC1 patients for 
which urinary uromodulin data were available, this combined clinical and biochemical score 
separated ADTKD-UMOD from ADTKD-MUC1 with an improved AUC of 0.89 (95% CI 0.82; 
0.96, p<0.001). The cut-off value of ≥5 still appears as the optimal cut-off value to discriminate 
ADTKD-UMOD from ADTKD-MUC1 (Youden index 0.684) with a sensitivity of 94.1% and 
specificity of 74.3% and a NPV 89.7%, PPV 84.2% for a UMOD mutation (Table S5 and Figure 
7B). Based on the clinical and biochemical UMOD score, we suggest a diagnostic algorithm to 




This international cohort study represents the largest dataset of ADTKD-UMOD and ADTKD-
MUC1 patients reported to date, providing new insights into the phenotype and disease 
progression of the main subtypes of ADTKD. Because of the autosomal dominant inheritance 
and regional familial clustering, considerable differences in the prevalence of ADTKD-
subgroups are mentioned in national cohorts 2,16,21. In this international ADTKD cohort, 
ADTKD-UMOD represents the most frequent subtype of ADTKD with an estimated prevalence 
of 37.1%, followed by ADTKD-MUC1 in 35.1% of UMOD-negative families and an estimated 
overall prevalence of 21.0%. Of note, a systematic effort to screen for mutations inHNF1B, 
REN, DNAJB11 and SEC61A1 is ongoing in the 133 UMOD- and MUC1-negative families; and 
for mutations in MUC1 in the 141 UMOD-negative families in the registry.   
Based on the large sample size, we observed distinct features in the clinical presentation 
of ADTKD-UMOD and ADTKD-MUC1, with relevance for clinical practice and patient 
counselling. Kidney disease appears more severe in ADTKD-MUC1, with a higher prevalence of 
ESKD (58% vs. 44% in ADTKD-UMOD, p=0.04), an earlier onset of ESKD (36 years vs. 46 
years in ADTKD-UMOD, p<0.001) and a shorter median renal survival (46 years vs. 54 years in 
ADTKD-UMOD, p=0.013). Previous studies reported an older age at ESKD (Mean: 44.9 years) 
in ADTKD-MUC1 patients 8, which could be explained by inclusion of historically affected 
patients (clinically affected relatives of genetically diagnosed patients) whereas we only included 
individuals with an established genetic diagnosis. The heterogeneity of ADTKD-MUC1 in terms 
of CKD and/or renal disease progression is intriguin  and suggests considerable modifier effects.  
Gout has been classically described in patients with UMOD mutations. Indeed, our data 
suggest that gout is strikingly more prevalent and of significantly earlier onset in ADTKD-
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UMOD compared to ADTKD-MUC1. Defective urinary concentration resulting in polydipsia 
and polyuria has been described in ADTKD-UMOD patients, most likely because of impaired 
activity of TAL-based Na+-K+-2Cl--cotransporter NKCC2 16,18. Plasma volume contraction and 
compensatory higher reabsorption activity of the proximal tubule including upregulation of Na+-
coupled urate transporters most likely explain the hyperuricemia phenotype in ADTKD-UMOD 
24,25. A similar mechanism was shown in aged Umod KO mice that displayed reduced activity of 
NKCC2 25. Even though ADTKD-MUC1 presumably originates from the distal tubule, gout was 
considerably less prevalent in this disorder.  
We investigated two cardinal biological features decribed in ADTKD-UMOD with 
likely pathophysiological relevance: aberration in uromodulin export mechanisms and induction 
of ER stress. Based on the observation that mucin-1 is expressed in the distal kidney tubule 
including the TAL where it colocalizes with uromodulin 6 and on the observation that MUC1fs is 
accumulating in other mucin-1-expressing tissues (skin, breast, lung, colon) without causing 
extrarenal manifestations 7, one could hypothesize that MUC1fs might interact with uromodulin 
in TAL. Yet, in contrast to ADTKD-UMOD, we found no difference in the urinary level of 
uromodulin between ADTKD-MUC1 patients and the normal population. Furthermore, analysis 
of MUC1-mutant kidney biopsies revealed a normal distribution of uromodulin in TAL cells, 
without evidence for ER stress (GRP78 expression) - a hallmark of ADTKD-UMOD. These 
novel findings suggest that the processing of uromodulin is not altered in ADTKD-MUC1 and 
that ER stress is not a main finding in ADTKD-MUC1. In line, a recent study found entrapment 
of MUC1fs in vesicles of the early secretory pathway in models of ADTKD-MUC1 20. 
Previous reports described intracellular accumulation of uromodulin in kidney biopsies 
from ADTKD-UMOD patients 1,2. However, such staining is not available in a large number of 
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patients, preventing us to speculate on its value in clinical decision making. In our experience, 
the uromodulin staining is operator-dependent, requi ing rigorous positive and negative controls, 
and it might depend on the underlying UMOD mutation. Furthermore, the availability of kidney 
biopsies is restricted. The assessment of urinary uromodulin levels in patients at time of 
diagnosis and during disease progression might offer a non-invasive diagnostic tool and 
biomarker in ADTKD-UMOD. Since urinary uromodulin levels show a positive correlation with  
eGFR (for eGFR <90mL/min/1.73m2) and tubular mass 26,27, they need to be normalized for 
residual eGFR and interpreted against matched controls. Based on data from a large control 
cohort, we show here that urinary uromodulin (in mg/g creatinine to account for urine 
concentration) normalized for eGFR can be applied in the clinical setting of ADTKD.  
A recent study based on exome sequencing reported mutations in UMOD accounting for 
~3% of all patients with a genetic finding in this cohort 13. However, considerable hurdles in the 
diagnostic approach of ADTKD-subtypes persist. These include but are not limited to: (i) limited 
availability of MUC1 testing due to technical challenges; (ii) lack of validated diagnostic/genetic 
algorithm due to unappreciated clinical differences b tween ADTKD subtypes; and (iii) missing 
disease biomarkers due to small and scattered disease cohorts. For everyday practice and cost-
effectiveness, practical tools such as scoring system  are very useful to guide genetic testing 1. 
The Belgo-Swiss Registry was instrumental in delineating a clinical UMOD-score because it 
revealed key discriminatory clinical features, including positive family history of CKD and/or 
gout; age at presentation; prevalence of kidney disease and progression to ESKD; history of 
gout. Of interest, renal cysts are less common in ADTKD-UMOD patients, in line with previous 
studies 15,16,21. The delineated clinical UMOD-score showed an excellent negative predictive 
value for UMOD mutations (cut-off ≥5) in the Belgo-Swiss Registry (NPV: 94.3%) and in the
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US ADTKD registry (NPV: 91.0%). As ADTKD-UMOD and ADTKD-MUC1 present 
considerable clinical overlap, we were not surprised that the clinical UMOD-score separated 
modestly between these two entities (AUC 0.69). Yet, higher UMOD-score values showed a 
solid specificity for UMOD mutations (e.g. cut-off ≥8: specificity of 83.7% and PPV of 81.3% 
for an UMOD mutation). Adding urinary uromodulin measurements, a pathophysiological 
biomarker for ADTKD-UMOD, considerably increased the discriminating power of the score 
(AUC 0.89) with a positive predictive value of 84.2% for an UMOD mutation (cut-off ≥5 
points). Since the progression of kidney disease and the prevalence and onset of gout seems 
dependent on the underlying genetic diagnosis, a genetic diagnosis is recommended as it might 
impact on the management of ADTKD patients, e.g. follow-up, scheduling of renal 
transplantation and gout-preventive strategies. Furthermore, targeted therapies might be in reach 
at least for ADTKD-MUC1.  
The limits of this study include the retrospective “r al-life” cohort design of 
consecutively recruited patients, with inherent difficulties such as limited access to full clinical 
information, missing DNA samples for further genetic testing and lack of strict 
inclusion/exclusion criteria. We included all genetically resolved cases of a given family, 
potentially introducing the risk for selection bias. However, we estimate that this represents a 
neglectable risk as only 1-2 patients were in general included per family and considerable 
intrafamilial clinical variability exists in ADTKD 8,28. Since kidney biopsies are rarely performed 
in these diseases and yield non-specific findings (e.g. interstitial fibrosis, tubular atrophy), we 
did not to include histopathology information in the analysis. A survey of histopathology results 
from the Belgo-Swiss Registry showed that interstitial fibrosis with tubular atrophy (in ca. 60% 
of available pathology reports) and interstitial nephritis (in ca. 40% of available pathology 
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reports) were the preponderant histological findings  ADTKD-UMOD and UMOD-negative 
patients. A more detailed histological description of biopsies performed in ADTKD-UMOD and 
ADTKD-MUC1 warrants a dedicated analysis.  
It should be pointed that systematic screening for UMOD mutations in all 10 coding 
exons has only been performed in a subset of ADTKD patients. Based on previous screens and 
WES, we estimate that very few UMOD mutations outside exons 3 and 4 might have been 
missed in ADTKD-UMOD 13,16. Furthermore, large deletions or insertions in UMOD are not 
detected by direct sequencing methods. With the availability of gene panel testing and NGS 
approaches, the utility of a clinical score in directing targeted gene testing will probably 
decrease. However, at the current stage, MUC1 mutations are missed by NGS and availability of 
specialized testing is limited. To the best of our knowledge, clinical-grade genetic testing for 
MUC1 is only performed by the Broad Institute (Cambridge, MA, USA). For these reasons, we 
estimate that simple clinical and biochemical tools t  estimate pre-test probability impacts on 
diagnostic work-up and potentially reduces the costs a sociated with unjustified genotyping.  
In conclusion, this large international retrospective cohort study provides a detailed 
phenotype analysis of ADTKD-UMOD and ADTKD-MUC1 patients. The clinical hallmarks of 
the two most common ADTKD subtypes are hyperuricemia and early gout in ADTKD-UMOD 
and a heterogeneous, but generally more severe kidny disease in ADTKD-MUC1. The clinical 
UMOD-score is a sensitive and, coupled to urinary uromodulin levels, potentially specific tool to 
select patients for genetic UMOD testing. These results should help clinicians to improve 
diagnostic rates, clinical management and patient counselling in ADTKD.  
19 
 
Material and Methods 
International ADTKD Cohort 
The International ADTKD Cohort consists of patients from the Belgo-Swiss ADTKD Registry 
and the US ADTKD Registry (see below). The inclusion criteria were those defined by the 
KDIGO consensus 2, including: a family history compatible with autosomal dominant 
inheritance of chronic kidney disease (CKD) with features of ADTKD including progressive loss 
of kidney function, bland urinary sediment, absent-to-mild albuminuria/proteinuria, normal or 
small-sized kidneys on ultrasound; and/or (in absence of a positive family history of CKD) a 
history of early-onset hyperuricemia/gout and/or the presence of interstitial fibrosis/tubular 
atrophy on kidney biopsy. Exclusion criteria included: a different genetic diagnosis (non-
ADTKD), the presence of enlarged cystic kidneys, proteinuria (>1g/24h) and/or consistent 
hematuria, longstanding or uncontrolled diabetes mellitus or arterial hypertension and the 
consumption of drugs linked to tubulointerstitial nephritis. Only patients screened for UMOD 
and/or MUC1 mutations were included in the Cohort. Anonymized d mographics, clinical and 
genetic information were recorded in a database. This study was approved by the institutional 
review board of Wake Forest School of Medicine, Winsto -Salem, NC; the UCLouvain Medical 
School, Brussels; and the European Community's 7th Framework Programme “European 
Consortium for High-Throughput Research in Rare Kidney Diseases (EURenOmics).  
Belgo-Swiss ADTKD Registry: The Belgo-Swiss ADTKD Registry has been developed by 
academic partners with input from clinicians in Belgium and Switzerland. In 2019, the registry 
includes 275 patients enrolled since 2003. The clinical data included a family pedigree, onset and 
evolution of kidney function decline, onset of hyperuricemia/gout (age of gout onset was defined 
as the patient’s age at the first episode of gouty arthritis) and fractional excretion of uric acid, 
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imaging and histopathology data (where available) and information on potential extrarenal 
manifestations (e.g. pancreatic enzymes, liver functio  tests). ESKD was defined as 
eGFR<10mL/min or initiation of renal replacement therapy (dialysis or kidney transplantation).  
US ADTKD Registry: The US ADTKD Registry includes families with tubulointerstitial kidney 
disease referred to Wake Forest School of Medicine (Winston-Salem, NC) since 1999. 
Information collected included demographics, pedigree, age of ESKD (defined as above), 
laboratory values, and ultrasound results.  
 
Genetic testing 
Informed written consent was obtained from all patients. Genomic DNA was isolated from 
peripheral blood leukocytes using standard procedures and DNA was stored at 4°C.  
UMOD testing: Direct sequencing of UMOD exons was initially performed by Sanger 
sequencing, as previously described 29. More recently, UMOD gene is analyzed by massive 
parallel sequencing using a tubulopathy gene panel designed by the work package tubulopathies 
of the European Consortium EURenOmics 30,31 Mutational analysis was carried out in exons 3 
and 4 for all enrolled patients and in all 10 coding exons for a subset of patients. 
MUC1 genotyping was performed using a MUC1 VNTR sequencing approach coupled to a 
spectrometry-based probe extension assay as previously described 7,32. MUC1 testing was 
provided by the Broad Institute of MIT and Harvard, Cambridge, MA 32 and the 1st Faculty of 
Medicine, Charles University, Prague, Czech Republic 7. Nucleotide numbering reflects cDNA 
numbering with +1 corresponding to the A of the ATG translation initiation codon in the 
reference sequence (NM_003361.3). Alamut®Visual software 
(www.interactivebiosoftware.com) was used to assist in determining variant pathogenicity. 
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Identified variants were successively checked against relevant databases, such as Clinvar 
(https://www.ncbi.nlm.nih.gov/clinvar/), HGMD (http://www.hgmd.cf.ac.uk/ac/index.php), 
Varsome (https://varsome.com/) and local databases to a sess for previous publication.  
Variants were considered disease-causing based on previous reports, family segregation analysis 
or prediction algorithms (SIFT, Align GVD, mutation taster and Polyphen2) for pathogenicity.  
The variants were classified according to the guidelines published by the American College of 
Medical Genetics ACMG 2015 33. Variants of interest were verified by Sanger sequencing. 
 
Measurements of urinary levels of uromodulin 
A validated ELISA method was used to measure urinary uromodulin levels (second morning 
urine sample) from 86 patients with ADTKD 22. Urinary creatinine was measured using a 
Synchron DXC800 analyzer (Beckman Coulter, Fullerton, CA) and used to normalize for urine 
concentration. The reference samples (n=2717) were obtained from the Cohorte Lausannoise 
(CoLaus), a population-based study including 6000 people aged 35–75 years from the city of 
Lausanne, Switzerland 23. eGFR was calculated using the CKD-EPI equation. Informed consent 
was obtained from all participating individuals.  
 
Uromodulin expression constructs 
cDNA of human wild type uromodulin was cloned in pcDNA 3.1(+) (Thermofisher, Waltham, 
MA) and an HA tag was inserted after the leader peptid  in between T26 and S27 in the protein 
sequence34. The C150S and L284P mutant isoforms were obtained by mutagenesis using the 
Quickchange Lightning mutagenesis kit (Agilent, Santa Clara, CA) following the manufacturer’s 
instructions. Primers were designed using the software QuikChange® Primer Design Program. 
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Primers used for mutation C150S: forward (5’->3’) gatggcactgtgagtcctccccgggctcctg, reverse 
(5’->3’) caggagcccggggaggactcacagtgccac and for mutation L248P: forward (5’->3’) 
cccgagtgtcacccggcgtactgcaca, reverse (5’->3’) tgtgcagtacgccgggtgacactcggg.  
 
Cell culture conditions 
HEK293 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 
10% Fetal Bovine Serum (FBS), 200 U/ml penicillin, 200 μg/ml streptomycin and 2 mM 
glutamine at 37°C, 5% CO2. HEK293 cells were transfected using lipofectamine 2000 
(Thermofisher) following the manufacturer’s protocol and analyzed 24 h after transfection. 
 
Western blot 
Cells were lysed in octylglucoside lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 60 mM 
octyl β-D-glucopyranoside, 10 mM NaF, 0.5 mM Sodium orthovanadate, 1 mM 
glycerophosphate and protease inhibitor cocktail (Sigma)) for 1 h at 4 °C under rotation followed 
by 10 min centrifugation at 17,000 g. Soluble fractions were quantified by the Bio-Rad Protein 
Assay (Bio-Rad). Western blot experiments were performed as described in Schaeffer et al 34. 
Antibodies: Mouse purified anti-HA.11 Epitope Tag antibody (Cat# 901502, Biolegend, San 
Diego, CA, dilution 1:1,000), mouse monoclonal anti-β-actin (A2228, Sigma, dilution 1:20,000). 
 
Immunofluorescence  
Kidney biopsies: Immunodetection of uromodulin and GRP78 was performed on 5 μm-thick 
kidney sections obtained from nephrectomy samples of ADTKD- UMOD (Female, 41-year-old, 
ESKD; Male, 42-year-old, ESKD) and ADTKD-MUC1 patients (Female, 60-year-old, ESKD; 
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Male, 47-year-old, ESKD). Slides were deparaffinized in xylene and rehydrated in a graded 
ethanol series. Antigen retrieval was carried out fr 10 minutes with citrate buffer (pH 6.0) at 
98°C. After 20 minutes in blocking solution, slides were incubated overnight with GRP78 
primary antibody (1/300; Abcam ab21685), followed by incubation with AlexaFluor555-
conjugated goat anti-rabbit antibody for 45 minutes (1/200; Invitrogen). The slides were probed 
with sheep anti-uromodulin primary antibody (1/800; Meridien Life Science Inc. K90071C), 
followed by AlexaFluor488-conjugated donkey anti-sheep (1/200; Invitrogen). Coverslips were 
mounted with Prolong gold antifade reagent with 4′,6-diamidino-2-phenylindole (DAPI, 
Invitrogen) and analyzed under a Zeiss LSM 510 Meta Confocal microscope (Carl Zeiss, Jena, 
Germany) with high numerical aperture lenses (Plan-Neofluar 20x/0.5). The use of these samples 
has been approved by the UCLouvain Ethical Review Board 35. 
HEK293 cells: Cells grown on coverslip were fixed in 4% paraformaldehyde (PFA) for 15 min, 
permeabilized 10 min with 0.5 % triton and blocked 30 min with 10 % donkey serum. Cells were 
labelled for 1 h 30 min at room temperature with a mouse purified anti-HA.11 Epitope Tag 
antibody (Cat# 901502, Biolegend, dilution 1:500) and  rabbit polyclonal anti-calreticulin 
(C4606, Sigma, dilution 1:500) followed by 1h incubation with the appropriate Alexa-Fluor 
conjugated secondary antibodies (Thermofisher, dilution 1:500). Cells were stained with 4,6-
diamidino-2-phenylindole (DAPI) and mounted using fluorescence mounting medium (DAKO, 
Agilent). All pictures were taken with an UltraVIEW ERS spinning disk confocal microscope 
(UltraVIEW ERS-Imaging Suite Software, Zeiss 63X/1.4; PerkinElmer Life and Analytical 
Sciences Boston, MA). All images were imported in Photoshop CS (Adobe Systems, Mountain 




Generation and validation of the ADTKD-UMOD score 
The weighted UMOD-score was based on ADTKD-criteria, specific clinical haracteristics of 
ADTKD-UMOD (i.e. early gout onset and hyperuricemia) and parameters that are negatively 
associated with ADTKD (ie. providing alternative explanation for CKD: proteinuria/hematuria, 
diabetes/uncontrolled hypertension, renal cysts/enlarged kidneys) 2,16,21. For weighting the items 
of the score, we used integer values between -1 and +3. A score of +2 was given for the general 
ADTKD-criteria 2; +1 or +3, for the UMOD-specific clinical and laboratory findings; and -1 for
each negatively-associated item. The score was first tested in the Belgo-Swiss ADTKD Registry 
and validated in the US ADTKD Registry. In order to discriminate ADTKD-UMOD from 
ADTKD-MUC1, we defined a normal range of urinary uromodulin (mg/g creatinine/eGFR) 
using 2717 urine samples from the general population. Based on the pathophysiology of 
ADTKD-UMOD, on previous reports 36 as well as on our findings (Figure 5A), we assigned 
respectively +1 and +3 points for urinary uromodulin values between the median and 25th
percentile and below the 25th percentile of normal urinary uromodulin levels. Similarly, we 
assigned respectively -1 and -3 points for urinary uromodulin values between the median and 
75th percentile and above the 75th percentile of normal urinary uromodulin levels. 
Conceptualization of the score was based on the previously published HNF1β score 37.  
 
Statistical analysis 
Quantitative parameters are presented as median and i terquartile range (25th to 75th 
percentiles) (for scale variables) or means ± standard eviation (for continuous variables), and 
qualitative parameters are presented as fractions with percentages. Categorical variables were 
compared using the chi-squared test. Continuous variables were compared using the Mann–
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Whitney U test or unpaired t-test. ANOVA testing with Tukey’s multiple comparison test was 
used to compare urinary uromodulin levels. Kaplan-Meier curves were generated to display 
ESKD- and gout-free survival. Patients who had not reached ESKD or developed gout at the end 
of the study (outcome of interest not occurred during follow-up time) were considered as 
censored individuals. Censoring time was defined as age at last follow-up. A log-rank test was 
used for comparison of survival curves. The performance of the UMOD score was assessed by 
calculating the area under the curve of the receiver op rating characteristic (ROC) curve. The 
Youden’s index was used to define the optimal discriminatory cut-off point for the UMOD-score. 
Statistical analysis was performed using SPSS Statistics (Armonk, NY: IBM Corp). p<0.05 was 
considered statistically significant, two sided tests were used. 
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Figure 1. Design and flowchart of mutation detection in the International ADTKD Cohort 
aClinical characteristics of ADTKD are based on the KDIGO Consensus Report 2, see Material & 
Methods for more details.  
n=number of patients; N=number of families. ADTKD, autosomal dominant tubulointerstitial 
kidney disease; CKD, chronic kidney disease; UMOD, gene encoding uromodulin; MUC1, gene 
encoding mucin-1. 
 
Figure 2. Spectrum of mutations in UMOD and MUC1 
A: UMOD gene and protein domain structure with the 106 UMOD mutations reported in the 
International Cohort depicted relative to domain localization. Mutations involving cysteine 
residues are indicated in italics, on top of each box. B: Prevalence of different UMOD mutations: 
missense mutations (101/106; 95.3%), affecting cysteine (57/106; 53.8%) or non-cysteine 
(44/106; 41.5%) amino acids and insertion/deletions (5/106; 4.7%). C: MUC1 gene exon-intron 
structure (middle panel) and normal protein structure (above) with the 4 detected mutations (in 
red) in the variable number tandem repeat (VNTR) domain and the consequence on protein 
structure (below). TM, transmembrane domain; SEA domain, self-cleavage module. D:
Prevalence of identified MUC1 mutations in reported ADTKD-MUC1 families.  
 
Figure 3. Clinical characteristics of ADTKD-UMOD and ADTKD-MUC1 
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A: Quantitative parameters are presented as median and quartiles or means±SD. Qualitative 
parameters are presented as fractions with percentag s. Chi-square test for categorial variables, 
Mann-Whitney U and unpaired t-test for quantitative parameters were used. # and $ represent 
gender comparison within ADTKD-UMOD and ADTKD-MUC1, respectively. Column n 
(UMOD/MUC1) denotes the number of ADTKD-UMOD and ADTKD-MUC1 patients analyzed 
for the respective parameter. Abbreviations: CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; ESKD, end stage kidney disease. B: Scatter plots for age at ESKD and 
onset of gout for ADTKD-UMOD and ADTKD MUC1 patients. Bars indicate means±SD. 
 
Figure 4. Freedom from ESKD and gout in ADTKD-UMOD and ADTKD-MUC1 
A: Kaplan-Meier curve of renal survival in ADTKD-UMOD and ADTKD-MUC1 patients. 
Median renal survival was 54 years (95% CI, 51.5-56.5) in ADTKD-UMOD and 46 years (95% 
CI, 39.3-52.7) in ADTKD-MUC1. B: Kaplan-Meier gout-free survival curve in ADTKD-UMOD 
and ADTKD-MUC1 patients. Median gout-free survival was 30 years (95% CI, 27.3-32.7) in 
ADTKD-UMOD and 67 years (95% CI, 57.9-76.1) in ADTKD-MUC1. Log rank test was used. 
Censored: event of interest has not occurred during the follow-up time. 
 
Figure 5. Uromodulin processing in ADTKD-UMOD and ADTKD-MUC1 
A: Urinary uromodulin excretion normalized to urinary c eatinine (mg/g creatinine) (left panel) 
and normalized to urinary creatinine and eGFR (mg/g creatinine/eGFR) (right panel) in 
ADTKD-MUC1 patients, ADTKD-UMOD patients and a reference population. Median, 25th 
percentile and 75th percentile values in the reference population are indicted in Figure 5A right 
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panel. Numerical values (median and quartiles) for urinary uromodulin, eGFR and sample size 
are below the graph. Outlier removed with GraphPad (ROUT Q=1%), One-way ANOVA 
p<0.0001 for both graphs, Tukey’s multiple comparison test was applied. B: 
Immunofluorescence staining for uromodulin (green) a d GRP78 (red) in ADTKD-MUC1, 
ADTKD-UMOD and normal human kidney (NHK) biopsy. Scale bar: 50µm 
 
Figure 6. Clinical UMOD-score and performance in the Belgo-Swiss ADTKD Registry 
A: Clinical UMOD-score based on clinical, biochemical, histological and imaging data. 
Attributed points for specific characteristics are shown on the right. a After routine work-up 
including urinary sediment and urinalysis, kidney imaging; b Interstitial fibrosis, tubular atrophy, 
thickening and lamellation of tubular basement membranes, tubular dilatation (microcysts), 
negative immunofluorescence for complement and immunoglobulins; c Proteinuria >300mg/dL, 
persistent hematuria (both eumorphic and dysmorphic) in repeated urinalysis; d HbA1c >10% or 
repeated blood pressure measurements > 160/100mmHg and/or corresponding clinical findings 
of hypertensive cardiopathy/nephropathy; e ≥1 cyst at any location diagnosed by 
ultrasonography, CT-scan or MRI. Example: 35-year-old patient, gout onset 32y (+1), serum uric 
acid 550μmol/L (+3), eGFR 55mL/min/1.73m2, bland urine analysis and sediment, kidneys 
without cysts and normal size on MRI, no diabetes or hypertension (+2 for CKD of unknown 
origin), family history of CKD documented on three g nerations (+2), total clinical UMOD-score 
of 8 points. Abbreviations: CKD, chronic kidney disease; ADTKD, autosomal dominant 
tubulointerstitial kidney disease. B: Receiver operating characteristics (ROC) curve of the 
clinical UMOD-score in the Belgo-Swiss Registry (n=211 ADTKD patien s with available data), 
AUC 0.72 , 95% CI 0.66; 0.79, p<0.001, the cut-off value of ≥5 has a sensitivity of 98.1% and 
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specificity of 41.4% for UMOD mutation, NPV 94.3%, PPV 59.1%. C: Histogram of clinical 
UMOD-score results in UMOD-positive (n=106) and UMOD-negative (n=105) patients. The red 
horizontal line indicates the cut-off value of 5. 
 
Figure 7. UMOD-score comparing ADTKD-UMOD vs. ADTKD-MUC1 in the US ADTKD 
Registry 
A: Left panel: Receiver operating characteristics (ROC) curve of the clinical UMOD-score in the 
US Registry (n=205 ADTKD-UMOD and MUC1 patients with available data), AUC 0.69 , 95% 
CI 0.62; 0.77, p<0.037. A cut-off value of ≥8 has a sensitivity of 48.8% and specificity of 83.7% 
for UMOD mutations, while a cut-off value of ≥5 has a sensitivity of 97.6% and specificity of 
15.0% for UMOD mutations. Right panel: Histogram of clinical UMOD-score results in 
ADTKD-UMOD (n=125) and ADTKD-MUC1 (n=80) patients. B: Left panel: Receiver 
operating characteristics (ROC) curve of the clinical UMOD-score including urine uromodulin 
levels in the US Registry (n= 86 ADTKD-UMOD and MUC1 patients with available urinary 
uromodulin data), AUC 0.89 , 95% CI 0.82; 0.96, p<0.001. The cut-off value of ≥5 has the 
highest Youden index for discrimination (0.684) and has a sensitivity of 94.1% and specificity of 
74.3% for UMOD mutation, NPV 89.7%, PPV 84.2%. Right panel: Histogram of clinical + 
urinary uromodulin UMOD-score results in ADTKD-UMOD (n=51) and ADTKD-MUC1 (n=35) 
patients. The red horizontal line indicates the cut-off value of 5. 
 
Figure 8. Diagnostic algorithm for suspected ADTKD based on clinical UMOD-score and 
urinary uromodulin levels  
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aProgressive loss of renal function, bland urinary sediment, normal-to-mild 
albuminuria/proteinuria, normal sized kidneys on ultrasound, no consumption of drugs linked to 
tubulointerstitial nephritis. 
bAssessed by validated ELISA and normalized to urinary creatinine and eGFR. Obtained values 
should be interpreted against UMOD-negative family members or reference populations 26,27. See 
results and discussion section for more details. 
cFor diagnostic algorithm including other ADTKD genes, refer to Devuyst et al.1. Alternative 
diagnosis include nephronophthisis (autosomal recessiv ), ADPKD (large cystic kidneys), 
autosomal dominant glomerulopathies (proteinuria/hematuria), other causes of tubulointerstitial 
kidney disease (autoimmune, TINU) including drugs and toxins (NSAID, aristolochic acid, 
calcineurin inhibitors, lithium). 
Abbreviations: ADTKD, autosomal dominant tubulointerstitial kidney disease; CKD, chronic 



























Age at presentation (y) 45 (31; 58) 34 (22; 49) 49 (37; 62) 174/377 
Positive family history  
(Gout/CKD) (%) 
625/679 (92) 191/227 (84) 434/451 (96)  
eGFR at diagnosis (mL/min) 44.3 ± 30.0 45.1 ± 20.9 43.8 ± 34.3 137/229 
CKD (%) 492/586 (84) 205/258 (80) 287/328 (88)  
ESKD (%) 
- Age at ESKD (y) 
216/503 (43) 
44 (32; 55) 
70/258 (27) 
44 (33; 56) 
146/245 (60) 
44 (32; 55) 
 
245/146 
Serum uric acid (µmol/L) 
- Female 
- Male 
472.0 ± 140.7 
452.2 ± 148.8 
485.4 ± 133.7 
479.4 ± 145.3 
456.7 ± 158.4 
493.8 ± 135.2 
454.6 ± 128.4 
443.1 ± 128.7 



















Age at gout onset (y) 
- Female 
- Male 
30 (20; 45) 
35 (22; 50) 
28 (20; 40) 
31 (20; 47) 
40 (23; 56) 
30 (20; 41) 
30 (21; 40) 
35 (22; 50) 














Quantitative parameters are presented as median and quartiles or means±SD. Qualitative parameters are presented as fractions with 
percentages. N=families, n=patients; Column n(BE-CH/US) denotes the number of patients from the Belgo-Swiss and US Registry 
analyzed for the respective parameter; BE-CH, Belgo-Swiss; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; 
ESKD, end-stage kidney disease.  
 
Figure 1
Inclusion criteria for ADTKD:
- Family history compatible with autosomal dominant inheritance of CKD fulfilling the clinical characteristics of ADTKDa
- In absence of a positive family history of CKD:
• Demonstration of tubulointerstitial damage on kidney biopsy or
• History of early-onset hyperuricemia and/or gout
Exclusion criteria:
- Different genetic diagnosis (non-ADTKD)
- Enlarged cystic kidneys
- Proteinuria (>1g/24h) and/or consistent hematuria
- Longstanding/uncontrolled diabetes mellitus/arterial hypertension
International ADTKD Cohort (N=585; n=726)
N=429 families (n=451 patients) from US Registry N=156 families (n=275 patients) from Belgo-Swiss Registry
1st Screening: UMOD mutations
N=562; n=703 
1st Screening: MUC1 mutations
N=23; n=23





ADTKD-MUC1 in UMOD-negative 
N=72/205 (35.1%)
n=83/218 (38.1%)
ADTKD-MUC1 total: N=93; n=104



































W202C, C217G, C217R,  
C223Y, S237C, C248W, 
G253C, W258C, C267F, 
G269C, G270C, C282R, 
C282S, Y286C, C287Y  
G201D, W202S, Y203D,  
R204G, R204P, G210S,  
R222P, T225K, T225M, 
M229R, W230R, P236L, 
P236R, P236S, H250L, 










A461E  T469M, G488R 
Y272del
C32Y, C32W, C41Y, C52S, C52Y, C63S, 
C69R, N76K/C77G, C77R,C77Y, 
C83R, C92G, C92R, C92Y, 
C94W, G103C, C106F, 
C106G, C106Y, C112R, 
C120R, C126R, C135F, 
C135S, C135W, C135Y, 
C148R, C148S, C148Y  
E34K, A39T, G55S, 


























































































n (UMOD/MUC1) p-value 











Age at presentation (y) 42 (27;53) 47 (37; 57) 218/78 0.005 
Positive family history (Gout/CKD) (%) 243/257 (95) 69/80 (86)  0.007 
eGFR at presentation (mL/min) 39.2 ± 20.3 50 ± 51.9 136/52 0.157 
CKD (%) 231/257 (90) 53/80 (66)  <0.001 
ESKD (%) 




46 (39; 57)  
44 (40; 55) 
50 (39; 58) 
46/80 (58) 
36 (30; 46)  
34 (28; 46) 











Serum uric acid (µmol/L) 
- Female 
- Male 
497.9 ± 136.6 
478.7 ± 133.2 
515.7 ± 138.5 
443.6 ± 121.7 
418.7 ± 136.1 


























Age at gout onset (y) 
- Female 
- Male 
27 (19; 37) 
30 (21; 43) 
26 (18; 34) 
45 (29; 51) 
28 (21; 41) 






































































































eGFR: 55.5 (51.7; 58.0)
uUMOD: 14.7 (8.6; 22.6)
ADTKD-MUC1 (n=35)
eGFR: 55.1 (45.0; 68.3)
uUMOD: 15.7 (9.7; 22.0)
ADTKD-UMOD (n=51)
eGFR: 51.6 (37.0; 69.2)




eGFR: 78.0 (70.3; 84.1)
uUMOD: 0.23 (0.14; 0.35)
ADTKD-MUC1 (n=35)
eGFR: 55.1 (45.0; 68.3)
uUMOD: 0.29 (0.22; 0.36)
ADTKD-UMOD (n=53)
eGFR: 53.5 (37.0; 73.6)


































AUC = 0.72 











Family history of CKD or early gout (<40y) compatible with autosomal
dominant inheritance
+ 2
CKD of unknown origina + 2
Age at gout onset 
<30 years + 3
>30 years + 1
Serum uric acid
>500 µmol/L (>8.41mg/dL) + 3
<500 µmol/L (<8.41mg/dL) + 1
Histological findings compatible with ADTKDb + 2
Proteinuria/Hematuriac - 1
Diabetes/Uncontrolled hypertensiond - 1
Renal cysts/Enlarged kidneyse - 1
A
AUC =  0.89
(95% CI, 0.82; 0.96)
AUC =  0.69
(95% CI, 0.62; 0.77)


















































Test for MUC1 or other ADTKD genes
or consider alternative diagnosisc
negativepositive
Criteria for suspecting a diagnosis of ADTKD
− Family history compatible with autosomal dominant inheritance of CKD 
fulfilling the clinical characteristics of ADTKDa
− In absence of a positive family history of CKD:
• Demonstration of tubulointerstitial damage on kidney biopsy or
• History of early-onset hyperuricemia and/or gout
Clinical UMOD-score +
urinary uromodulinb
<5≥5
5-7
urine uromodulin
not available
